JPRN-jRCTs031180005已完成3 期
JCOG1213: Randomized phase III study of etoposide plus cisplatin combination therapy versus irinotecan plus cisplatin combination therapy in advanced neuroendocrine carcinoma of the digestive system. - TOPIC-NEC
OKUSAKA Takuji0 个研究点目标入组 170 人开始时间: 2019年1月23日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 170
研究概览
简要总结
A randomized phase III study was conducted in patients with unresectable or recurrent NEC of gastrointestinal or hepatobiliary origin, and the overall survival of EP and IP arms was tested in a two-sided manner. In the primary analysis for all enrolled patients, there was no significant difference in survival. There was also no significant difference in the sensitivity analyses for all eligible patients and those eligible for central pathological diagnosis. Please find the detailed summary in the CSR.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 75age old（—）
- 性别
- All
入选标准
- •1) Histologically proven neuroendocrine carcinoma (NEC).
- •2) NEC arise in esophagus, stomach, duodenum, intestine, appendix, colon, rectum, gallbladder, intrahepatic bile duct, extrahepatic bile duct, ampulla of Vater, pancreas, and liver.
- •3) Unresectable or recurrent cancer; Patients with the following are not eligible: cT4, no distant metastasis rather than supraclavicular lymph node, or stenosis indicated for palliative radiotherapy for esophageal NEC.
- •4) No previous chemotherapy or radiotherapy for NEC. Pre- or post-operative chemotherapy except irinotecan or etoposide for NEC is allowed as long as it was completed at least 8 weeks prior to registration.
- •5) No previous chemotherapy using platinum agents for any malignancies.
- •6) Aged 20 to 75 years old.
- •7) ECOG performance status of 0 or 1.
- •8) Measurable region is not required.
- •9) Adequate organ functions.
- •10) Written informed consent.
排除标准
- •1) Synchronous or metachronous (within 5 years) malignancies except carcinoma in situ or intramucosal tumor curatively treated with local therapy.
- •2) Active infection requiring systemic therapy.
- •3) Fever of 38 degrees Celsius or higher.
- •4) Pregnant or lactating women, women of childbearing potential, or women within 28 days after delivery.
- •5) Psychiatric disease.
- •6) Patients requiring systemic steroids medication.
- •7) Interstitial pneumonia, pulmonary fibrosis.
- •8) Serious co-existing illness.
- •9) Unstable angina pectoris within 3 weeks, or with a history of myocardial infarction within 6 months.
- •10) Impossible to use both iodine and gadolinium due to being allergic to contrast agent.
- •11) Uncontrolled diabetes mellitus or routine administration of insulin.
研究者
相似试验
已完成
3 期
Randomized phase III study of etoposide plus cisplatin combination therapy versus irinotecan plus cisplatin combination therapy in advanced neuroendocrine carcinoma of the digestive system. (JCOG1213,TOPIC-NEC)advanced neuroendocrine carcinoma of the digestive systemJPRN-UMIN000014795Japan Clinical Oncology Group (JCOG)170
进行中（未招募）
2 期
Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic OriginNeuroendocrine CarcinomaNCT02687958Gruppo Oncologico Italiano di Ricerca Clinica30
终止
2 期
Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone for the Treatment of TNBC (TRYbeCA-2)Triple Negative Breast CancerNCT03674242ERYtech Pharma27
已完成
2 期
Clinical Trial to Evaluate the Safety and Efficacy of JP-1366 in Patients With Erosive Gastroesophageal Reflux DiseaseGERDNCT04282954Onconic Therapeutics Inc.188
已完成
3 期
A Study Comparing Etoposide/Cisplatin With Irinotecan/Cisplatin to Treat Extensive Disease Small Lung CancerSmall Cell Lung CancerNCT00349492Clinical Research Center for Solid Tumor, Korea372